Combination therapy using the small interfering RNA bevasiranib

Retina

Volumn 29, Issue SUPPL. 6, 2009, Pages

  Singerman, Lawrence ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; Antivascular endothelial growth factor agents; Bevasiranib; Combination therapy; Small interfering RNA

Indexed keywords

BEVASIRANIB; MESSENGER RNA; RANIBIZUMAB; SMALL INTERFERING RNA; VASCULOTROPIN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; HUMAN; NONHUMAN; NOTE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; GENE SILENCING; HUMANS; MACULAR DEGENERATION; MICE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68049118572     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181ad2341     Document Type: Note

References (5)

1. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9:210-216. (Pubitemid 38097589)
2. Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis 2008;14:997-1005. (Pubitemid 351803426)
3. Karagiannis TC, El-Osta A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther 2005;12:787-795. (Pubitemid 43086280)
4. Data presented at American Academy of Ophthalmology meeting, Chicago, IL, October 2005.
5. Kleinman ME, Yamada K, Takeda A, et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452:591-597.